443 related articles for article (PubMed ID: 19433292)
1. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
3. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
4. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
5. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
[TBL] [Abstract][Full Text] [Related]
6. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
8. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
9. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
10. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
Rabban JT; Glidden D; Kwan ML; Chen YY
Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
[TBL] [Abstract][Full Text] [Related]
11. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
[TBL] [Abstract][Full Text] [Related]
13. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
14. Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer.
Timovska YO; Pivnyuk VM; Oliynichenko GP; Anikushko MF; Zachartseva LM; Chekhun VF
Exp Oncol; 2009 Dec; 31(4):231-6. PubMed ID: 20010529
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
Costa SD; Loibl S; Kaufmann M; Zahm DM; Hilfrich J; Huober J; Eidtmann H; du Bois A; Blohmer JU; Ataseven B; Weiss E; Tesch H; Gerber B; Baumann KH; Thomssen C; Breitbach GP; Ibishi S; Jackisch C; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Jan; 28(1):83-91. PubMed ID: 19901111
[TBL] [Abstract][Full Text] [Related]
16. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
17. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
18. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
Patel T; Gupta A; Shah M
J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
[TBL] [Abstract][Full Text] [Related]
19. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
20. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.
Wang J; Buchholz TA; Middleton LP; Allred DC; Tucker SL; Kuerer HM; Esteva FJ; Hortobagyi GN; Sahin AA
Cancer; 2002 Jun; 94(12):3107-14. PubMed ID: 12115341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]